132 related articles for article (PubMed ID: 33001012)
1. An Agathokakological Tale of Δ
Mathew B; Harilal S; Musa A; Kumar R; Parambi DGT; Jose J; Uddin MS; Shah MA; Behl T; Unnikrishnan MK
Curr Drug Targets; 2021; 22(7):823-834. PubMed ID: 33001012
[TBL] [Abstract][Full Text] [Related]
2. Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells.
Galanti G; Fisher T; Kventsel I; Shoham J; Gallily R; Mechoulam R; Lavie G; Amariglio N; Rechavi G; Toren A
Acta Oncol; 2008; 47(6):1062-70. PubMed ID: 17934890
[TBL] [Abstract][Full Text] [Related]
3. Synthetic cannabinoids JWH-018, JWH-122, UR-144 and the phytocannabinoid THC activate apoptosis in placental cells.
Almada M; Alves P; Fonseca BM; Carvalho F; Queirós CR; Gaspar H; Amaral C; Teixeira NA; Correia-da-Silva G
Toxicol Lett; 2020 Feb; 319():129-137. PubMed ID: 31730886
[TBL] [Abstract][Full Text] [Related]
4. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB
Wang XF; Galaj E; Bi GH; Zhang C; He Y; Zhan J; Bauman MH; Gardner EL; Xi ZX
Br J Pharmacol; 2020 Apr; 177(8):1865-1880. PubMed ID: 31877572
[TBL] [Abstract][Full Text] [Related]
5. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response.
McKallip RJ; Nagarkatti M; Nagarkatti PS
J Immunol; 2005 Mar; 174(6):3281-9. PubMed ID: 15749859
[TBL] [Abstract][Full Text] [Related]
6. Cell death induction and intracellular vesicle formation in human colorectal cancer cells treated with Δ
Hwang YN; Kwon IS; Park JH; Na HH; Kwon TH; Park JS; Kim KC
Genes Genomics; 2023 Dec; 45(12):1463-1474. PubMed ID: 37837516
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.
Marcu JP; Christian RT; Lau D; Zielinski AJ; Horowitz MP; Lee J; Pakdel A; Allison J; Limbad C; Moore DH; Yount GL; Desprez PY; McAllister SD
Mol Cancer Ther; 2010 Jan; 9(1):180-9. PubMed ID: 20053780
[TBL] [Abstract][Full Text] [Related]
8. Effects of tetrahydrocannabinols on human oral cancer cell proliferation, apoptosis, autophagy, oxidative stress, and DNA damage.
Semlali A; Beji S; Ajala I; Rouabhia M
Arch Oral Biol; 2021 Sep; 129():105200. PubMed ID: 34146926
[TBL] [Abstract][Full Text] [Related]
9. Modulation of Delta9-tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase and aromatase.
Takeda S; Yamamoto I; Watanabe K
Toxicology; 2009 May; 259(1-2):25-32. PubMed ID: 19428940
[TBL] [Abstract][Full Text] [Related]
10. Δ9-tetrahydrocannabinol suppresses cytotoxic T lymphocyte function independent of CB1 and CB 2, disrupting early activation events.
Karmaus PW; Chen W; Kaplan BL; Kaminski NE
J Neuroimmune Pharmacol; 2012 Dec; 7(4):843-55. PubMed ID: 21789506
[TBL] [Abstract][Full Text] [Related]
11. Δ9-THC-caused synaptic and memory impairments are mediated through COX-2 signaling.
Chen R; Zhang J; Fan N; Teng ZQ; Wu Y; Yang H; Tang YP; Sun H; Song Y; Chen C
Cell; 2013 Nov; 155(5):1154-1165. PubMed ID: 24267894
[TBL] [Abstract][Full Text] [Related]
12. Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol.
Lile JA; Kelly TH; Pinsky DJ; Hays LR
Psychopharmacology (Berl); 2009 Apr; 203(2):241-50. PubMed ID: 19018520
[TBL] [Abstract][Full Text] [Related]
13. Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol.
Springs AE; Karmaus PW; Crawford RB; Kaplan BL; Kaminski NE
J Leukoc Biol; 2008 Dec; 84(6):1574-84. PubMed ID: 18791168
[TBL] [Abstract][Full Text] [Related]
14. Differential role of the nitric oxide pathway on delta(9)-THC-induced central nervous system effects in the mouse.
Azad SC; Marsicano G; Eberlein I; Putzke J; Zieglgänsberger W; Spanagel R; Lutz B
Eur J Neurosci; 2001 Feb; 13(3):561-8. PubMed ID: 11168564
[TBL] [Abstract][Full Text] [Related]
15. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.
Pertwee RG
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3353-63. PubMed ID: 23108552
[TBL] [Abstract][Full Text] [Related]
16. Delta9-tetrahydrocannabinol is a full agonist at CB1 receptors on GABA neuron axon terminals in the hippocampus.
Laaris N; Good CH; Lupica CR
Neuropharmacology; 2010; 59(1-2):121-7. PubMed ID: 20417220
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity.
van der Stelt M; Veldhuis WB; Bär PR; Veldink GA; Vliegenthart JF; Nicolay K
J Neurosci; 2001 Sep; 21(17):6475-9. PubMed ID: 11517236
[TBL] [Abstract][Full Text] [Related]
18. Phytocannabinoid Pharmacology: Medicinal Properties of
Sampson PB
J Nat Prod; 2021 Jan; 84(1):142-160. PubMed ID: 33356248
[TBL] [Abstract][Full Text] [Related]
19.
Pellati F; Borgonetti V; Brighenti V; Biagi M; Benvenuti S; Corsi L
Biomed Res Int; 2018; 2018():1691428. PubMed ID: 30627539
[TBL] [Abstract][Full Text] [Related]
20. Δ9-Tetrahydrocannabinol targeting estrogen receptor signaling: the possible mechanism of action coupled with endocrine disruption.
Takeda S
Biol Pharm Bull; 2014; 37(9):1435-8. PubMed ID: 25177025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
